Innovation in bone healing and tissue repair

17 Dec 15
Full Statement of the board of directors on the request of Kuros Biosurgery AG regarding the absence of an obligation to make an offer
15 Dec 15
Invitation to Extraordinary Shareholders’ Meeting
03 Dec 15
Cytos Biotechnology and Kuros Biosurgery to combine to create Kuros Biosciences
12 Aug 15
Cytos exclusively licenses its VLP platform for the treatment of Cancer to Checkmate Pharmaceuticals LLC
29 Jul 15
Cytos Biotechnology Ltd Reports the Financial Results of the First Half Year 2015
29 Jun 15
Annual Shareholders’ Meeting of Cytos Biotechnology Ltd: Shareholders approve all resolutions
08 Jun 15
Invites to the Annual General Meeting
08 May 15
Cytos’ bond conversion into equity effective
04 May 15
Cytos will become debt-free
28 Apr 15
Cytos Biotechnology Ltd Reports the Financial Results of 2014
13 Apr 15
Extension of convertible bond listing at SIX Swiss Exchange
25 Mar 15
Novartis buys out CAD 106 license agreement for CHF 4 million
16 Mar 15
Extraordinary Shareholders’ Meeting of Cytos Biotechnology Ltd. approves all resolutions
13 Mar 15
The Higher Court of the Canton of Zurich approves the conversion of the convertible bonds into shares
19 Feb 15
Cytos Biotechnology Ltd. invites for an Extraordinary Shareholders’ Meeting
26 Jan 15
Bondholders’ meeting approves conversion of bonds into shares with overwhelming majority
26 Jan 15
Cytos Biotechnology Ltd holds a Bondholders’ meeting today. Trading of Cytos shares and convertible bonds temporarily suspended.
06 Jan 15
Bondholder Meeting
06 Jan 15
Cytos exclusively licenses its VLP platform for the treatment of hepatitis B infections to OnCore Biopharma

Select Year

 

Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kuros.ch

About Kuros

  1. Overview
  2. Executive Committee
  3. Board

Products

  1. Pipeline
  2. Orthobiologics
    Fracture repair
    KUR-111
    KUR-113
    MagnetOs
    Spinal fusion
    KUR-113
    MagnetOs
    Solitary Bone Cysts
    KUR-112
  3. Sealants
    Neuroseal (KUR-023)

Technologies

  1. Overview
  2. Surface Science Technology
  3. Synthetic Cross-Linking Technology
  4. Fibrin-Based
  5. Immune Modulation
  6. Publications

Partnerships

  1. Collaborations
  2. Business development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & presentations
  4. Calendar
  5. Corporate governance
  6. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Cytos Biotechnology Archive

17 Dec 15
Full Statement of the board of directors on the request of Kuros Biosurgery AG regarding the absence of an obligation to make an offer
15 Dec 15
Invitation to Extraordinary Shareholders’ Meeting
03 Dec 15
Cytos Biotechnology and Kuros Biosurgery to combine to create Kuros Biosciences
12 Aug 15
Cytos exclusively licenses its VLP platform for the treatment of Cancer to Checkmate Pharmaceuticals LLC
29 Jul 15
Cytos Biotechnology Ltd Reports the Financial Results of the First Half Year 2015
29 Jun 15
Annual Shareholders’ Meeting of Cytos Biotechnology Ltd: Shareholders approve all resolutions
08 Jun 15
Invites to the Annual General Meeting
08 May 15
Cytos’ bond conversion into equity effective
04 May 15
Cytos will become debt-free
28 Apr 15
Cytos Biotechnology Ltd Reports the Financial Results of 2014
13 Apr 15
Extension of convertible bond listing at SIX Swiss Exchange
25 Mar 15
Novartis buys out CAD 106 license agreement for CHF 4 million
16 Mar 15
Extraordinary Shareholders’ Meeting of Cytos Biotechnology Ltd. approves all resolutions
13 Mar 15
The Higher Court of the Canton of Zurich approves the conversion of the convertible bonds into shares
19 Feb 15
Cytos Biotechnology Ltd. invites for an Extraordinary Shareholders’ Meeting
26 Jan 15
Bondholders’ meeting approves conversion of bonds into shares with overwhelming majority
26 Jan 15
Cytos Biotechnology Ltd holds a Bondholders’ meeting today. Trading of Cytos shares and convertible bonds temporarily suspended.
06 Jan 15
Bondholder Meeting
06 Jan 15
Cytos exclusively licenses its VLP platform for the treatment of hepatitis B infections to OnCore Biopharma

Select Year